We observed that women who opted to receive chemotherapy, alone or in combination with anti-HER2 therapy, tended to be young (p < 0.001) and were more likely to have HER2-positive or triple-negative tumours (p < 0.001) (Table 4). The gene discussed is ERBB2; the disease is neoplasm.